Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 1 (2004), Issue 5 (December)

1. Noninvasive in vivo whole body luminescent analysis of luciferase labelled orthotopic prostate tumours.
   Eur J Cancer, 40(18): 2851-8. [Abstract] [Full-text]
2. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
   Eur J Cancer, 40(18): 2837-44. [Abstract] [Full-text]
3. AMP-activated protein kinase activity is required for vanadate-induced hypoxia-inducible factor 1alpha expression in DU145 cells.
   Carcinogenesis, 25(12): 2497-507. [Abstract] [Full-text]
4. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
   Cancer Res, 64(23): 8715-22. [Abstract] [Full-text]
5. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
   Cancer Res, 64(23): 8620-9. [Abstract] [Full-text]
6. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression.
   Cancer Res, 64(23): 8526-33. [Abstract] [Full-text]
7. Laparoscopic radical prostatectomy: early safety and efficacy.
   ANZ J Surg, 74(12): 1065-8. [Abstract] [Full-text]
8. Prostate cancer incidence and survival in relation to education (United States).
   Cancer Causes Control, 15(9): 939-45. [Abstract] [Full-text]
9. A prospective study of diet and prostate cancer in Japanese men.
   Cancer Causes Control, 15(9): 911-20. [Abstract] [Full-text]
10. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
    Oncogene, 23(56): 9034-41. [Abstract] [Full-text]
11. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
    Oncogene, 23(56): 9111-9. [Abstract] [Full-text]
12. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study.
    Am J Hum Genet, 76(1): 82-90. [Abstract] [Full-text]
13. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
    Steroids, 69(13): 795-801. [Abstract] [Full-text]
14. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy?
    Eur Urol, 47(1): 45-50; discussion 50-1. [Abstract] [Full-text]
15. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
    Eur Urol, 47(1): 38-44; discussion 44. [Abstract] [Full-text]
16. Non-invasive detection of prostate cancer by electromagnetic interaction.
    Eur Urol, 47(1): 29-37; discussion 37. [Abstract] [Full-text]
17. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
    Eur Urol, 47(1): 16-21. [Abstract] [Full-text]
18. Expression patterns of potential therapeutic targets in prostate cancer.
    Int J Cancer, 113(4): 619-28. [Abstract] [Full-text]
19. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2.
    Int J Cancer, 113(4): 561-7. [Abstract] [Full-text]
20. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells.
    Int J Cancer, 113(4): 660-9. [Abstract] [Full-text]
21. Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack.
    Prostate, 62(2): 105-14. [Abstract] [Full-text]
22. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Prostate, 62(2): 148-64. [Abstract] [Full-text]
23. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer.
    Prostate, 62(2): 140-7. [Abstract] [Full-text]
24. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.
    Prostate, 62(2): 165-86. [Abstract] [Full-text]
25. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action.
    Prostate, 62(2): 133-9. [Abstract] [Full-text]
26. Access of tumor-derived macromolecules and cells to the blood: an electron microscopical study of structural barriers in microvessel clusters in highly malignant primary prostate carcinomas.
    Prostate, 62(2): 123-32. [Abstract] [Full-text]
27. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer.
    Prostate, 62(2): 115-22. [Abstract] [Full-text]
28. Increased Nox1 and hydrogen peroxide in prostate cancer.
    Prostate, 62(2): 200-7. [Abstract] [Full-text]
29. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
    Prostate, 62(2): 187-99. [Abstract] [Full-text]
30. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
    Clin Cancer Res, 10(23): 8037-47. [Abstract] [Full-text]
31. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Clin Cancer Res, 10(23): 8018-27. [Abstract] [Full-text]
32. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.
    Clin Cancer Res, 10(23): 7994-8004. [Abstract] [Full-text]
33. Immune-based therapies for prostate cancer.
    Immunol Lett, 96(1): 3-9. [Abstract] [Full-text]
34. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis.
    Proc Natl Acad Sci U S A, 101(49): 17204-9. [Abstract] [Full-text]
35. Prostate cancer and sexuality: implications for nursing.
    Geriatr Nurs, 25(6): 341-7. [Abstract] [Full-text]
36. Barriers to planning and conducting a screening: prostate cancer.
    Geriatr Nurs, 25(6): 336-40. [Abstract] [Full-text]
37. Unwanted control: how patients in the primary care setting decide about screening for prostate cancer.
    Patient Educ Couns, 56(1): 116-24. [Abstract] [Full-text]
38. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
    Int J Radiat Oncol Biol Phys, 60(5): 1631-8. [Abstract] [Full-text]
39. Magnetic resonance assessment of prostate localization variability in intensity-modulated radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 60(5): 1611-21. [Abstract] [Full-text]
40. Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery.
    Int J Radiat Oncol Biol Phys, 60(5): 1602-10. [Abstract] [Full-text]
41. MR and CT image fusion for postimplant analysis in permanent prostate seed implants.
    Int J Radiat Oncol Biol Phys, 60(5): 1572-9. [Abstract] [Full-text]
42. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.
    Int J Radiat Oncol Biol Phys, 60(5): 1373-8. [Abstract] [Full-text]
43. Impact of knee support and shape of tabletop on rectum and prostate position.
    Int J Radiat Oncol Biol Phys, 60(5): 1364-72. [Abstract] [Full-text]
44. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
    Int J Radiat Oncol Biol Phys, 60(5): 1347-50. [Abstract] [Full-text]
45. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing.
    Free Radic Biol Med, 38(1): 50-7. [Abstract] [Full-text]
46. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?
    Cancer Genet Cytogenet, 156(1): 31-6. [Abstract] [Full-text]
47. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
    Mol Cancer, 3: 31. [Abstract] [Full-text]
48. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis.
    Cancer, 101(12): 2755-9. [Abstract] [Full-text]
49. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Cancer, 101(12): 2881-91. [Abstract] [Full-text]
50. Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma.
    Cancer, 101(12): 2744-54. [Abstract] [Full-text]
51. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies.
    Clin Sci (Lond), 108(1): 1-11. [Abstract] [Full-text]
52. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
    Urology, 64(6): 1238-43. [Abstract] [Full-text]
53. Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model.
    Urology, 64(6): 1233-7. [Abstract] [Full-text]
54. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
    Urology, 64(6): 1231.e1-3. [Abstract] [Full-text]
55. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
    Urology, 64(6): 1182-6. [Abstract] [Full-text]
56. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
    Urology, 64(6): 1177-81. [Abstract] [Full-text]
57. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.
    Urology, 64(6): 1171-6. [Abstract] [Full-text]
58. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
    Urology, 64(6): 1165-70. [Abstract] [Full-text]
59. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Urology, 64(6): 1160-4. [Abstract] [Full-text]
60. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study.
    Int J Cancer, 113(5): 819-24. [Abstract] [Full-text]
61. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers.
    Int J Cancer, 113(5): 811-8. [Abstract] [Full-text]
62. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study.
    Int J Cancer, 113(5): 835-40. [Abstract] [Full-text]
63. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
    J Clin Invest, 114(12): 1774-81. [Abstract] [Full-text]
64. Macronutrients, fatty acids, cholesterol and prostate cancer risk.
    Ann Oncol, 16(1): 152-7. [Abstract] [Full-text]
65. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).
    Cytokine, 29(2): 56-66. [Abstract] [Full-text]
66. Autopsy case of prostate cancer with multiple endocrine neoplasia 2A.
    Pathol Int, 54(12): 918-23. [Abstract] [Full-text]
67. Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus.
    Hum Genet, 116(1): 43-50. [Abstract] [Full-text]
68. Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases.
    Support Care Cancer, 12(12): 882-4. [Abstract] [Full-text]
69. Three-dimensional conformal radiotherapy in the treatment of prostate cancer in Australia and New Zealand: Report on a survey of radiotherapy centres and the proceedings of a consensus workshop.
    Australas Radiol, 48(4): 502-8. [Abstract] [Full-text]
70. Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer.
    Australas Radiol, 48(4): 493-501. [Abstract] [Full-text]
71. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells.
    Oncogene, 23(58): 9326-35. [Abstract] [Full-text]
72. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer.
    Cancer Gene Ther, 12(1): 90-100. [Abstract] [Full-text]
73. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer.
    Endocrinology, 146(1): 13-8. [Abstract] [Full-text]
74. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
    Cancer Res, 64(24): 9209-16. [Abstract] [Full-text]
75. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling.
    Cancer Res, 64(24): 9185-92. [Abstract] [Full-text]
76. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
    Cancer Res, 64(24): 9144-51. [Abstract] [Full-text]
77. Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5'-monophosphate dehydrogenase.
    Cancer Res, 64(24): 9049-56. [Abstract] [Full-text]
78. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus.
    Cancer Res, 64(24): 8906-10. [Abstract] [Full-text]
79. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells.
    Cancer Res, 64(24): 8867-75. [Abstract] [Full-text]
80. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells.
    Cancer Res, 64(24): 8860-6. [Abstract] [Full-text]
81. Polycyclic aromatic hydrocarbon-DNA adducts in prostate cancer.
    Cancer Res, 64(24): 8854-9. [Abstract] [Full-text]
82. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion.
    Cancer Res, 64(24): 8826-30. [Abstract] [Full-text]
83. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation.
    Biochem Biophys Res Commun, 326(4): 752-8. [Abstract] [Full-text]
84. Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR.
    Mol Cell Endocrinol, 229(1): 103-10. [Abstract] [Full-text]
85. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns.
    Clin Biochem, 38(1): 58-65. [Abstract] [Full-text]
86. Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease.
    Urol Oncol, 22(6): 485-9. [Abstract] [Full-text]
87. The association between obesity and the progression of prostate and renal cell carcinoma.
    Urol Oncol, 22(6): 478-84. [Abstract] [Full-text]
88. Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells.
    Urol Oncol, 22(6): 453-60. [Abstract] [Full-text]
89. Psychometric evaluation of the Cognitive Appraisal of Health Scale with patients with prostate cancer.
    J Adv Nurs, 49(1): 78-86. [Abstract] [Full-text]
90. Hyperbaric oxygen does not accelerate latent in vivo prostate cancer: implications for the treatment of radiation-induced haemorrhagic cystitis.
    BJU Int, 94(9): 1275-8. [Abstract] [Full-text]
91. Variation in patterns of practice in diagnosing screen-detected prostate cancer.
    BJU Int, 94(9): 1239-44. [Abstract] [Full-text]
92. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
    BJU Int, 94(9): 1235-8. [Abstract] [Full-text]
93. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
    Clin Chem, 51(1): 102-12. [Abstract] [Full-text]
94. gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis.
    Proc Natl Acad Sci U S A, 101(51): 17825-30. [Abstract] [Full-text]
95. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
    Prostate, 62(3): 233-42. [Abstract] [Full-text]
96. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
    Prostate, 62(3): 224-32. [Abstract] [Full-text]
97. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
    Prostate, 62(3): 217-23. [Abstract] [Full-text]
98. Stable expression of C/EBPalpha in prostate cancer cells down-regulates metallothionein and increases zinc-induced toxicity.
    Prostate, 62(3): 209-16. [Abstract] [Full-text]
99. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
    Prostate, 62(3): 299-306. [Abstract] [Full-text]
100. Ability of PSA-positive circulating macrophages to detect prostate cancer.
     Prostate, 62(3): 290-8. [Abstract] [Full-text]
101. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo.
     Prostate, 62(3): 282-9. [Abstract] [Full-text]
102. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
     Prostate, 62(3): 275-81. [Abstract] [Full-text]
103. Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer.
     Prostate, 62(3): 267-74. [Abstract] [Full-text]
104. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro.
     Prostate, 62(3): 253-9. [Abstract] [Full-text]
105. Explaining racial differences in prostate cancer in the United States: sociology or biology?
     Prostate, 62(3): 243-52. [Abstract] [Full-text]
106. Post-laminectomy long-term survival of a patient with spinal cord compression secondary to metastatic prostate cancer.
     Int J Clin Oncol, 9(6): 520-2. [Abstract] [Full-text]
107. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
     J Med Chem, 47(27): 6716-29. [Abstract] [Full-text]
108. Basal cell adenoma of prostate.
     Urol Res, 32(6): 421-2. [Abstract] [Full-text]
109. Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells.
     Urol Res, 32(6): 406-10. [Abstract] [Full-text]
110. Myosin regulation in the migration of tumor cells and leukocytes within a three-dimensional collagen matrix.
     Cell Mol Life Sci, 62(1): 65-76. [Abstract] [Full-text]
111. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies.
     Eur J Cancer, 41(1): 61-70. [Abstract] [Full-text]
112. Malignant melanoma with gall bladder metastasis as a second neoplasm in the course of prostate cancer.
     Pathol Oncol Res, 10(4): 243-5. [Abstract] [Full-text]
113. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma.
     Cancer, 103(1): 11-21. [Abstract] [Full-text]
114. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
     Cancer, 103(1): 76-84. [Abstract] [Full-text]
115. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
     Int J Cancer, 113(6): 870-80. [Abstract] [Full-text]
116. Do dietary lycopene and other carotenoids protect against prostate cancer?
     Int J Cancer, 113(6): 1010-4. [Abstract] [Full-text]
117. Birth size and subsequent risk for prostate cancer: a prospective population-based study in Norway.
     Int J Cancer, 113(6): 1002-4. [Abstract] [Full-text]
118. Expression and functional role of CCR9 in prostate cancer cell migration and invasion.
     Clin Cancer Res, 10(24): 8743-50. [Abstract] [Full-text]
119. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
     Clin Cancer Res, 10(24): 8728-34. [Abstract] [Full-text]
120. A quantitative promoter methylation profile of prostate cancer.
     Clin Cancer Res, 10(24): 8472-8. [Abstract] [Full-text]
121. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.
     Clin Cancer Res, 10(24): 8460-4. [Abstract] [Full-text]
122. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
     Clin Cancer Res, 10(24): 8351-6. [Abstract] [Full-text]
123. Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin.
     Clin Cancer Res, 10(24): 8275-83. [Abstract] [Full-text]
124. Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
     Clin Cancer Res, 10(24): 8147-51. [Abstract] [Full-text]
125. Mitochondrial DNA haplotyping revealed the presence of mixed up benign and neoplastic tissue sections from two individuals on the same prostatic biopsy slide.
     J Clin Pathol, 58(1): 83-6. [Abstract] [Full-text]
126. Expression of prostate specific antigen in male breast cancer.
     J Clin Pathol, 58(1): 69-71. [Abstract] [Full-text]
127. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
     J Gene Med, 6(12): 1343-57. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.